Literature DB >> 27523281

EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1.

Biao Wang1, Jiqin Zhang1, Fei Song1, Mi Tian1, Bizhi Shi1, Hua Jiang1, Wen Xu1, Hai Wang1, Min Zhou1, Xiaorong Pan1, Jianren Gu1, Shengli Yang1, Liyan Jiang2, Zonghai Li3.   

Abstract

Dysregulation in iron metabolism can lead to a wide range of diseases including cancer. Iron-regulatory proteins (IRPs) and iron responsive elements (IREs) have been established as post-transcriptional regulators of intracellular iron homeostasis. The roles of other pathways involved in this process, however, remain largely unknown. Here we report that epidermal growth factor receptor (EGFR), an oncogenic driver, binds to and regulates the subcellular distribution of transferrin receptor 1(TfR1) through its tyrosine kinase activity and thus is required for cellular iron import. Inactivation of EGFR reduces the cell surface TfR1 expression, which leads to decreased iron import due to impaired TfR1-mediated iron uptake. This damaged iron assimilation results in cell cycle arrest and growth inhibition, which can be partially rescued by non-Tf-bound iron supplements. Evaluation of non-small cell lung cancer samples reveals a positive correlation between EGFR activation and membrane TfR1 expression. Our findings uncover a new role of EGFR in modulating cellular iron homeostasis through redistribution of TfR1, which is essential for cancer development and progression.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  EGFR; Iron homeostasis; TfR1; Tyrosine phosphorylation

Mesh:

Substances:

Year:  2016        PMID: 27523281     DOI: 10.1016/j.canlet.2016.08.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

Review 1.  Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.

Authors:  Sharleen V Menezes; Sumit Sahni; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2017-06-14       Impact factor: 5.157

Review 2.  Iron and Cancer.

Authors:  Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti
Journal:  Annu Rev Nutr       Date:  2018-08-21       Impact factor: 11.848

Review 3.  Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC.

Authors:  Yifan Zhang; Ruixue Guo; Jia Li; Liangming Zhu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-11-15       Impact factor: 3.000

Review 4.  Role of dietary iron revisited: in metabolism, ferroptosis and pathophysiology of cancer.

Authors:  Santhi Latha Pandrangi; Prasanthi Chittineedi; Rajasekhar Chikati; Joji Reddy Lingareddy; Meeravali Nagoor; Suresh Kumar Ponnada
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

5.  Analyzing the drivers of cancer relapse: hypocalcemia and iron absorption in hormone-dependent female cancers.

Authors:  Prasanthi Chittineedi; Santhi Latha Pandrangi; Ravi Shankar Bellala; Sungey Naynee Sánchez Llaguno; Gooty Jaffer Mohiddin; Juan Alejandro Neira Mosquera; Venkata Madhavi Bellala; Viswa Kalyan Kolli
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 6.  Targeted Liposomes: A Nonviral Gene Delivery System for Cancer Therapy.

Authors:  Marcela Tavares Luiz; Jessyca Aparecida Paes Dutra; Larissa Bueno Tofani; Jennifer Thayanne Cavalcante de Araújo; Leonardo Delello Di Filippo; Juliana Maldonado Marchetti; Marlus Chorilli
Journal:  Pharmaceutics       Date:  2022-04-08       Impact factor: 6.525

Review 7.  Transferrin receptor 1 in cancer: a new sight for cancer therapy.

Authors:  Ying Shen; Xin Li; Dandan Dong; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

Review 8.  Iron and Cancer: 2020 Vision.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Cancer Res       Date:  2020-09-14       Impact factor: 12.701

9.  Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients.

Authors:  Christopher J Greene; Kristopher Attwood; Nitika J Sharma; Kenneth W Gross; Gary J Smith; Bo Xu; Eric C Kauffman
Journal:  Oncotarget       Date:  2017-11-06

10.  Blocking transferrin receptor inhibits the growth of lung adenocarcinoma cells in vitro.

Authors:  Yihe Wu; Jinming Xu; Jinbo Chen; Meirong Zou; Aizemaiti Rusidanmu; Rong Yang
Journal:  Thorac Cancer       Date:  2017-12-29       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.